Preclinical development at TPD Summit 2026
Oct 26–29, 2026 Boston, MA ~300 attendees Website
22 organizations at TPD Summit 2026 present work in preclinical development: 15 drug developers, 6 technology and service providers and 1 academic, government or non-profit body. Between them they bring 30 presentations to the program. Most represented: Genentech (2 on the program), Protai (2 on the program), Novartis (2 on the program). As of Oct 20, 2026.
Format
Top represented
Showing 1–16 of 22 organizations
| Organization | TPD Summit 2026 Attendance |
|---|---|
Genentech South San Francisco, CA | |
Biotechnology company and Roche Group member that discovers, develops and markets medicines. | Talk Tue Oct 27 12:30pm Talk Thu Oct 29 9:30am Optimizing the Next Generation Degraders with Better Informatics, Descriptors & Predictive Modeling AI & computational design Panel Thu Oct 29 10:00am |
Combines proteomics and AI to discover drug targets, biomarkers and degraders. | Panel Tue Oct 27 3:10pm Talk Wed Oct 28 11:30am Proteomics & AI Platform Maps Degrader-Induced Ternary Complex Diversity to Enable Rational Degrader Design AI & computational designScreening, assays & proteomics Panel Thu Oct 29 10:00am |
Novartis Basel, Switzerland | |
Swiss pharmaceutical company developing and marketing medicines in oncology, immunology, cardiovascular disease and neuroscience. | Talk Tue Oct 27 5:00pm Modelling Targeted Protein Degradation from Cells to the Clinic AI & computational design Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy |
Develops cancer therapeutics built on p27 biology, including molecular glue stabilizers, for drug-resistant cancers. | Panel Tue Oct 27 3:10pm Talk Thu Oct 29 12:15pm Locktacs for Intrinsically Disordered Proteins: First-in-Class p27 Molecular Glue Stabilizers Induced proximity beyond degradation |
Eli Lilly Indianapolis, IN | |
Global pharmaceutical company; its TuneLab platform offers biotechs AI models trained on Lilly research data. | Talk Tue Oct 27 4:30pm Accelerating Drug Discovery with Lilly TuneLab’s Federated Computing Platform AI & computational design Panel Thu Oct 29 10:00am |
Georgia Institute of Technology Atlanta, GA | |
Public research university in Atlanta, Georgia. | Talk Mon Oct 26 3:15pm GlueFinder: A Data-Driven Framework for the Rational Discovery of Molecular Glues AI & computational designDegrader discovery & design Panel Tue Oct 27 3:10pm |
Develops targeted protein stabilization therapeutics that recruit deubiquitinases to rescue proteins rather than degrade them. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Wed Oct 28 2:00pm The Journey to DUBTAC Clinical Candidates Induced proximity beyond degradation |
◇Program Partner | |
Supplies human and animal biospecimens and ADME-Tox products and runs in vitro ADME and related research services for drug developers. | Talk Tue Oct 27 2:00pm |
Evotec Hamburg, Germany | ◇Program Partner |
Drug discovery and development partner with its own molecular glue and degrader platforms and programs, alongside research services. | Talk Tue Oct 27 12:00pm Expanding the Molecular Glue Landscape to Enable Program Generation Across Multiple Therapeutic Areas Degrader discovery & design |
ICE Bioscience Beijing, China | ◇Program Partner |
Integrated drug discovery CRO with biology, DMPK and translational platforms taking programs from target identification to preclinical candidate. | Talk Tue Oct 27 3:10pm Decoding RIPTAC Mechanism of Action: Deep Data Mining & Target-Effector Pair Differentiation in Novel Proximity-Based Therapeutics Induced proximity beyond degradation |
Pelago Bioscience Solna, Sweden | ◇Innovation Partner |
Service provider measuring drug–target engagement in cells and tissues with its CETSA technology, now adding chemistry capability. | Talk Tue Oct 27 3:00pm From Binder Discovery to Translational Profiling: CETSA® for Targeted Protein Degradation Screening, assays & proteomics |
Biogen Cambridge, MA | |
Develops and markets therapies for neurological and neurodegenerative diseases, including multiple sclerosis and Alzheimer's disease. | Panel Tue Oct 27 3:10pm |
Discovers molecular glue degraders with a bacteria-based positive selection screening system. | Talk Tue Oct 27 2:30pm From Microbes to Degradation: Developing a b-catenin Degrader – From Bacteria to in-vivo Screening, assays & proteomics |
Develops cancer therapies that reprogram cancer cell death, including the BCL-xL degrader DT2216. | Talk Tue Oct 27 11:30am |
GluBio Therapeutics Hangzhou, China | |
Molecular glue degrader developer with research centers in Shanghai and San Diego, working in cancer, autoimmune and genetic diseases. | Talk Wed Oct 28 2:30pm |
Engineers biologics that deeply and selectively remove disease-driving proteins, such as autoantibodies, in immune disorders. |
Instantly find 20 buyers in preclinical development
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TPD Summit 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction